FDA Clears First Factor XIa Inhibitor, Setting Benchmark for a Crowded Class

The FDA approved Bayer's asundexian on November 9, 2026, the first factor XIa inhibitor to reach the US market and the first regulatory template for a mechanism that Bristol Myers Squibb and Johnson & Johnson are also chasing. The 50-mg once-daily tablet, branded Sunharbo, is indicated with antiplatelet therapy for secondary stroke prevention after a mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. For portfolio teams in the factor XI field, the label now defines the trial design, end points and exclusion language the rest of the class will be measured against.

"Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke," said Hylton Joffe, MD, MMSc, director of CDER's Office of Cardiology, Hematology, Endocrinology, and Nephrology. "Today's approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention."

What did the pivotal trial measure?

The approval rests on OCEANIC-STROKE, a multicenter, randomized, double-blind, placebo-controlled phase 3 study enrolling 12,327 adults across 37 countries. Participants were randomized within 72 hours of symptom onset, and both arms received antiplatelet therapy. Over a median of 14.2 months, asundexian reduced ischemic stroke risk by 26% versus placebo.

The full results appeared in the New England Journal of Medicine in April 2026. Recurrent ischemic stroke occurred in 6.2% of asundexian patients versus 8.4% on placebo; disabling or fatal strokes fell from 3% to 2.1%. The cohort had a mean age of 68 years, and a quarter of participants were older than 75 — a subgroup that matters for the safety read.

"Until now, reducing stroke risk has often been associated with higher bleeding risk. These findings give us hope for a safer way to prevent recurrent strokes," said Ashkan Shoamanesh, co–principal investigator and senior scientist at the Population Health Research Institute.

What caveats sit in the safety data?

Overall major bleeding was similar between arms, but the claim of preserved hemostasis carries qualifiers. Major bleeding increased with asundexian in patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding was more common with the drug, and diarrhea was the most frequently reported adverse reaction. The FDA granted the application Fast Track and Priority Review designations.

The label also excludes stroke prevention in atrial fibrillation. That exclusion traces to Bayer's own history: in November 2023, the company stopped an earlier phase 3 trial after asundexian failed to match apixaban's efficacy in atrial fibrillation. Developers of milvexian, abelacimab and other factor XI candidates now know one indication where the mechanism succeeded and one where it did not.

Why does the mechanism matter?

Factor XIa inhibition rests on a hypothesis: blocking this upstream coagulation protein may prevent pathological clots while largely preserving normal hemostasis. "Patients at risk for stroke and other thromboembolic events really need drugs that reduce the risk of dangerous clots without increasing their bleeding risk, and targeting factor XIa may open this possibility," said Clay Johnston, MD, PhD, MPH, chief medical officer at Harbor Health.

One trial in one indication does not prove the hypothesis across the class. The 26% relative reduction came in a population already receiving antiplatelet therapy, and the bleeding signal in older patients remains an open question for postmarketing surveillance.

What should development and manufacturing teams watch?

The label carries drug-interaction language that will shape real-world prescribing. It does not recommend coadministration with drugs combining P-glycoprotein induction and strong CYP3A4 induction, such as carbamazepine; a clinical pharmacology study found carbamazepine lowered asundexian exposure by approximately 44%. The drug is not recommended in moderate or severe hepatic impairment and should be withheld at least 24 hours before elective surgery and after thrombolysis.

For commercial planning, interaction management, age-related bleeding risk and long-term daily dosing in a large secondary-prevention population will drive postmarketing safety monitoring and supply forecasts. With a novel mechanism now on the market, interaction data moves from regulatory footnote to prescribing reality — a shift every follower program in the factor XI class should model before its own filing.